Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Nahid, Payam ^a   Bliven, Erin E ^b   Kim, Elizabeth Y ^a   Mac Kenzie, William R ^b   Stout, Jason E ^c   Diem, Lois ^b   Johnson, John L ^d   Gagneux, Sebastien ^e,f   Hopewell, Philip C ^a   Kato Maeda, Midori ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^f SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

AFRICA; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL LINEAGE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; DRUG RESPONSE; DRUG SAFETY; GENE CONVERSION; GENE SEQUENCE; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYLOGENETIC TREE; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM SMEAR; TREATMENT DURATION;

ALGORITHMS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUBERCULOSIS, PULMONARY;

MYCOBACTERIUM TUBERCULOSIS;

EID: 77956540290     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010753     Document Type: Article

References (22)

1. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, et al. (2008) High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 6: e311.
2. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
3. Zheng H, Lu L, Wang B, Pu S, Zhang X, et al. (2008) Genetic basis of virulence attenuation revealed by comparative genomic analysis of Mycobacterium tuberculosis strain H37Ra versus H37Rv. PLoS ONE 3: e2375.
4. Cubillos-Ruiz A, Morales J, Zambrano MM (2008) Analysis of the genetic variation in Mycobacterium tuberculosis strains by multiple genome alignments. BMC Res Notes 1: 110.
5. Gagneux S, Small PM (2007) Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7: 328-337.
6. Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM (2004) Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci U S A 101: 4871-4876.
7. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, et al. (2006) Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103: 2869-2873.
8. Manca C, Tsenova L, Barry CE, 3rd, Bergtold A, Freeman S, et al. (1999) Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 162: 6740-6746.
9. Newton SM, Smith RJ, Wilkinson KA, Nicol MP, Garton NJ, et al. (2006) A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc Natl Acad Sci U S A 103: 15594-15598.
10. Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Troudt J, et al. (2007) The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 179: 522-531.
11. Nicol MP, Wilkinson RJ (2008) The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 102: 955-965.
12. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, et al. (2009) Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180: 273-280.
13. Tsolaki AG, Hirsh AE, DeRiemer K, Enciso JA, Wong MZ, et al. (2004) Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc Natl Acad Sci U S A 101: 4865-4870.
14. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, et al. (1997) Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A 94: 9869-9874.
15. Asiimwe BB, Koivula T, Kallenius G, Huard RC, Ghebremichael S, et al. (2008) Mycobacterium tuberculosis Uganda genotype is the predominant cause of TB in Kampala, Uganda. Int J Tuberc Lung Dis 12: 386-391.
16. van Soolingen D, Qian L, de Haas PE, Douglas JT, Traore H, et al. (1995) Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 33: 3234-3238.
17. Comas I, Homolka S, Niemann S, Gagneux S (2009) Genotyping of genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLoS ONE 4: e7815.
18. Cowley D, Govender D, February B, Wolfe M, Steyn L, et al. (2008) Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis 47: 1252-1259.
19. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, et al. (2008) The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 4: e1000034.
20. Thwaites G, Caws M, Chau TT, D'Sa A, Lan NT, et al. (2008) Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J Clin Microbiol 46: 1363-1368.
21. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, et al. (2009) Relapse Associated with Active Disease Caused by Beijing Strain of Mycobacterium tuberculosis. Emerg Infect Dis 15: 7.
22. van der Spuy GD, Kremer K, Ndabambi SL, Beyers N, Dunbar R, et al. (2009) Changing Mycobacterium tuberculosis population highlights clade-specific pathogenic characteristics. Tuberculosis (Edinb) 89: 120-125.